At the end of the latest market close, Citius Pharmaceuticals Inc. (CTXR) was valued at $1.04. In that particular session, Stock kicked-off at the price of $1.01 while reaching the peak value of $1.09 and lowest value recorded on the day was $1.01. The stock current value is $1.08.
Recently in News on December 15, 2020, Citius Holds Webinar Series on Conducting Mino-Lok Phase 3 Trial During COVID-19. – Infectious Disease experts provide review of CLABSI patient management in a restricted environment. You can read further details here
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Citius Pharmaceuticals Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $1.0900 on 01/05/21, with the lowest value was $1.0000 for the same time period, recorded on 01/04/21.
Citius Pharmaceuticals Inc. (CTXR) full year performance was 27.07%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Citius Pharmaceuticals Inc. shares are logging -45.18% during the 52-week period from high price, and 160.24% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.41 and $1.97.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 539271 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Citius Pharmaceuticals Inc. (CTXR) recorded performance in the market was 5.88%, having the revenues showcasing 9.87% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 61.20M, as it employees total of 10 workers.
The Analysts eye on Citius Pharmaceuticals Inc. (CTXR)
During the last month, 0 analysts gave the Citius Pharmaceuticals Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 1.0249, with a change in the price was noted +0.0500. In a similar fashion, Citius Pharmaceuticals Inc. posted a movement of +4.85% for the period of last 100 days, recording 772,883 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for CTXR is recording 0.01 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.01.
Technical rundown of Citius Pharmaceuticals Inc. (CTXR)
Raw Stochastic average of Citius Pharmaceuticals Inc. in the period of last 50 days is set at 52.15%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 36.65%. In the last 20 days, the company’s Stochastic %K was 25.53% and its Stochastic %D was recorded 21.28%.
Considering, the past performance of Citius Pharmaceuticals Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 5.88%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -22.30%, alongside a boost of 27.07% for the period of the last 12 months. The shares increased approximately by 0.93% in the 7-day charts and went up by -4.42% in the period of the last 30 days. Common stock shares were driven by 9.87% during last recorded quarter.